Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease

Abstract

Failed proteostasis is a well-documented feature of Alzheimer’s disease, particularly, reduced protein degradation and clearance. However, the contribution of failed proteostasis to neuronal circuit dysfunction is an emerging concept in neurodegenerative research and will prove critical in understanding cognitive decline. Our objective is to convey Alzheimer’s disease progression with the growing evidence for a bidirectional relationship of sleep disruption and proteostasis failure. Proteostasis dysfunction and tauopathy in Alzheimer’s disease disrupts neurons that regulate the sleep–wake cycle, which presents behavior as impaired slow wave and rapid eye movement sleep patterns. Subsequent sleep loss further impairs protein clearance. Sleep loss is a defined feature seen early in many neurodegenerative disorders and contributes to memory impairments in Alzheimer’s disease. Canonical pathological hallmarks, β-amyloid, and tau, directly disrupt sleep, and neurodegeneration of locus coeruleus, hippocampal and hypothalamic neurons from tau proteinopathy causes disruption of the neuronal circuitry of sleep. Acting in a positive-feedback-loop, sleep loss and circadian rhythm disruption then increase spread of β-amyloid and tau, through impairments of proteasome, autophagy, unfolded protein response and glymphatic clearance. This phenomenon extends beyond β-amyloid and tau, with interactions of sleep impairment with the homeostasis of TDP-43, α-synuclein, FUS, and huntingtin proteins, implicating sleep loss as an important consideration in an array of neurodegenerative diseases and in cases of mixed neuropathology. Critically, the dynamics of this interaction in the neurodegenerative environment are not fully elucidated and are deserving of further discussion and research. Finally, we propose sleep-enhancing therapeutics as potential interventions for promoting healthy proteostasis, including β-amyloid and tau clearance, mechanistically linking these processes. With further clinical and preclinical research, we propose this dynamic interaction as a diagnostic and therapeutic framework, informing precise single- and combinatorial-treatments for Alzheimer’s disease and other brain disorders. Graphical Abstract

Serotonergic dysfunction may mediate the relationship between alcohol consumption and Alzheimer’s disease

“…Interestingly, neurons and glia that contain abnormally phosphorylated tau also show a corresponding increase in markers of UPR activation [ 229 , 231 ]. Although healthy tau is an intrinsically disordered protein that does not undergo folding, pathological tau assumes a rigid conformation as NFTs form [ 232 ].…”

Sleep and Oxidative Stress: Current Perspectives on the Role of NRF2

“…The regulatory elements within the ARE sequences of these genes confer specificity to the NRF2 transcriptional signature, which varies according to cell type, intensity, and duration of the stimuli (Lee et al 2005 ; Bai et al 2019 ; Liu et al 2019 ). As mentioned, in the brain, these genes regulate a variety of biological processes involved in the physiology of sleep and its disturbances (Sandberg et al 2014 ; Zhou et al 2018 ; Hafycz and Naidoo 2019 ; Morrone et al 2023 ).…”

Investigation of the shared biological mechanisms and common biomarker APTAF1 of sleep deprivation and mild cognitive impairment using integrated bioinformatics analysis

“…Recent studies on acute and chronic SD have elucidated the cellular and molecular mechanisms underlying sleep loss and cognitive deficits. Sleep loss may contribute to cognitive impairment not only by influencing the homeostasis of proteins, such as amyloid-β and tau ( Xie et al, 2020 ; Morrone et al, 2023 ), but also by modifying neuro-immune cross-talk ( Kaneshwaran et al, 2019 ; Parhizkar et al, 2023 ). However, a complete understanding of the underlying mechanism is lacking.…”